Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

740 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Re: Bimal Bhindi, Jeffrey Graham, J. Connor Wells, et al. Deferred Cytoreductive Nephrectomy in Patients with Newly Diagnosed Metastatic Renal Cell Carcinoma. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2020.04.038: Cytoreductive Nephrectomy: To Whom and When?
Mollica V, Rizzo A, Massari F. Mollica V, et al. Among authors: massari f. Eur Urol Oncol. 2020 Aug;3(4):559-560. doi: 10.1016/j.euo.2020.05.011. Epub 2020 Jun 15. Eur Urol Oncol. 2020. PMID: 32553708 No abstract available.
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Santoni M, et al. Among authors: massari f. J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. J Urol. 2015. PMID: 25046616
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Iacovelli R, et al. Among authors: massari f. J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092. Epub 2014 Nov 26. J Urol. 2015. PMID: 25433306
Metabolic alterations in renal cell carcinoma.
Massari F, Ciccarese C, Santoni M, Brunelli M, Piva F, Modena A, Bimbatti D, Fantinel E, Santini D, Cheng L, Cascinu S, Montironi R, Tortora G. Massari F, et al. Cancer Treat Rev. 2015 Nov;41(9):767-76. doi: 10.1016/j.ctrv.2015.07.002. Epub 2015 Jul 9. Cancer Treat Rev. 2015. PMID: 26169313 Review.
Cabozantinib in Advanced Renal Cell Carcinoma: Is it a METEOR?
Ciccarese C, Massari F, Tortora G. Ciccarese C, et al. Among authors: massari f. Eur Urol. 2016 May;69(5):969-70. doi: 10.1016/j.eururo.2015.12.030. Epub 2015 Dec 24. Eur Urol. 2016. PMID: 26724839 No abstract available.
Adjuvant therapy in renal cell carcinoma.
Massari F, Di Nunno V, Ciccarese C, Graham J, Porta C, Comito F, Cubelli M, Iacovelli R, Heng DYC. Massari F, et al. Cancer Treat Rev. 2017 Nov;60:152-157. doi: 10.1016/j.ctrv.2017.09.004. Epub 2017 Sep 23. Cancer Treat Rev. 2017. PMID: 28992528 Review.
740 results